K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate Demonstrates Tumor-Selective Pharmacokinetics, Extensive Intratumoral Distribution and Superior Efficacy in Non-Clinical Animal Models

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

K-679-Unimicelle

More Like This

PR Newswire associated0

K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid Tumors

PR Newswire associated0

Qilu Pharmaceutical to Showcase Novel Anti-Cancer Drug QL1706 at ESMO Congress 2023

PR Newswire associated0

Experimental Drug Development Centre Announces the Presentation of Updated Data from the Phase 1 Study of Antibody-Drug Conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)

Iksuda to Present IKS014 Phase 1 Data at ESMO

Antibody-drug Conjugates Shift the Cancer Treatment Landscape: Novotech Whitepaper Examines Latest Clinical Trial Data

PR Newswire associated0

Experimental Drug Development Centre Granted U.S. FDA Fast Track Designation for Antibody-Drug Conjugate EBC-129 to Treat Pancreatic Ductal Adenocarcinoma

Iksuda Therapeutics announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science